Not precise but these two are indicative that it is not seen as a meagre revenue:
May 2015 : Feature
Biocon entered into an agreement with Mylan in June 2009 to co-develop biosimilars of monoclonal antibodies and recombinant proteins; again, in February 2013, both companies agreed to co-develop generic insulin analogs.
Under the terms of the deal, Biocon and Mylan will have co-exclusivity in certain markets, such as India; and in other markets, where Mylan has exclusive commercialization rights, profits are shared by both the companies.
Biocon said it plans to spend about 8-9% of its biopharma sales, as its key biosimilar programmes recombinant human Insulin (rh-Insulin), insulin glargine and trastuzumab are in advanced clinical development in phase 3, and are likely to hit the developed markets of US and Europe by 2017-18.
Biocon expects to see its biosimilars contributing about $200 million by 2018-19.
JUNE 2016… INTERVIEW of KMS
What kind of opportunity do you see for this drug?
This particular product trastuzumab, which is otherwise known as under the brand name of Herceptin, commands a market size of close to $7 billion. We expect to be in the market by 2018-19.
How long does it take between final approvals and product release?
We will be submitting our dossiers for marketing authorisation very soon. It takes about 12-18 months for the review process and thereafter we get the marketing authorisation. We should be ready to enter the market soon after that.
What is your financial agreement with Mylan?
We have a profit-sharing arrangement with Mylan. That is what will see us earning pretty large revenues from this particular time frame that I mentioned.
Can you shed some colour on the competitive landscape as far as this cancer drug is concerned? What kind of opportunity are you looking at?
Mylan is the one which is going to pursue the commercial opportunity. We expect they will try and garner as much of the market as they can.
It is difficult at this point in time to really talk about market share in real terms.
But suffice to say, it is a large opportunity and given the fact that these are very expensive drugs and discounting can actually lead to good payer acceptance, the market size could be quite attractive for both companies. [ http://www.thehindubusinessline.com/companies/biocon-upbeat-on-new-cancer-drug-to-tap-7billion-market/article8697322.ece]